Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08 2022 - 4:35PM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development and commercialization of targeted therapies
for women’s cancers, today announced plans to present two posters
related to nonclinical data for OP-1250, a potent, oral complete
estrogen receptor (ER) antagonist (CERAN) and a selective ER
degrader (SERD), at the upcoming American Association for Cancer
Research (AACR) Annual Meeting, being held April 8-13, 2022.
Details of the poster presentations are as follows:
Title: Precision run-on sequencing (PRO-seq)
analysis of a treatment time course in ER+ breast cancer cell lines
reveals the transcriptional changes underlying response to complete
estrogen receptor antagonist (CERAN)
OP-1250Abstract: 5375 Session
Category: Experimental and Molecular
TherapeuticsSession Title: Mechanisms of Drug
ActionSession Type: E-Poster
Title: OP-1250 prevents tumor spread in a model
of metastatic mutant ERα+
breast cancerAbstract: 1618 Session
Category: Tumor BiologySession Title:
Cell Line and Animal ModelsSession Date and Time:
Monday, April 11, 2022, 1:30 p.m. - 5:00 p.m.
CTLocation: New Orleans Convention Center, Exhibit
Halls D-H, Poster Section 11The poster presentations will be
available on Friday, April 8 at 1:00 p.m. ET on the conference
meeting platform and on Olema’s website under the Science
section.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
targeted therapies for women’s cancers. Olema’s lead product
candidate, OP-1250, is an orally-available small molecule with
combined activity as both a complete estrogen receptor (ER)
antagonist (CERAN) and a selective ER degrader (SERD). It is
currently being evaluated as a single agent in an ongoing Phase 1/2
clinical trial, and in Phase 1b combination with palbociclib, in
patients with recurrent, locally advanced, or metastatic
ER-positive (ER+), human epidermal growth factor receptor
2-negative (HER2-) breast cancer. Olema is headquartered in San
Francisco and has operations in Cambridge, Massachusetts.
Contact:
Eva Stroynowski
Vice President, Communications and Investor Relations
eva@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jul 2023 to Jul 2024